ZENTALIS PHARMACEUTICA

Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

16 9 2024 07:00:00 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024

09 9 2024 07:00:00 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 9 2024 16:40:50 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress

09 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 8 2024 18:00:00 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 7 2024 18:00:47 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program

18 6 2024 07:00:00 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 6 2024 18:00:55 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

30 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors

29 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting

23 5 2024 17:01:39 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit

14 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress

07 5 2024 07:00:01 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 5 2024 17:30:00 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024

02 4 2024 16:05:00 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 4 2024 17:30:00 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 3 2024 18:00:00 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

28 2 2024 07:00:00 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates

27 2 2024 07:00:00 提供 Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference

13 2 2024 07:00:00 提供 Nasdaq GlobeNewswire